496 AML Clinical Trials Recruiting Now (July 2026): Acute Myeloid Leukemia
Last updated: July 1, 2026
Current Clinical Trial Landscape
Active research areas in 2026:
- Menin inhibitors for NPM1-mutated and KMT2A-rearranged AML: revumenib, ziftomenib, bleximenib — all in Phase 3 in 2026 (covers ~30% of adult AML, NPM1 being the single most common AML mutation)
- Venetoclax-based combinations: backbone of both intensive induction and non-intensive (HMA + venetoclax) regimens; multiple Phase 3 maintenance and conditioning trials
- FLT3 inhibitors: gilteritinib, quizartinib, HEC73543, next-gen agents in frontline, post-transplant maintenance — and (new in 2026) expansion into FLT3-ITD negative AML
- IDH1/2 inhibitors: ivosidenib, enasidenib, dual IDH1/2 inhibitor HMPL-306 — combinations with HMA ± venetoclax
- Transplant optimization and cellular therapy: PT-Cy GVHD prophylaxis, MRD-guided conditioning, mocravimod, venetoclax-augmented conditioning, CAR-T
Already approved: Venetoclax + azacitidine, midostaurin/gilteritinib/quizartinib (FLT3), ivosidenib (IDH1), enasidenib (IDH2), revumenib (KMT2A-rearranged R/R acute leukemia, FDA 2024), gemtuzumab ozogamicin (CD33), CPX-351.
Post-ASCO 2026 update (June 13): The menin inhibitor class is the AML headline of 2026. Revumenib (KMT2A-rearranged R/R approval Nov 2024) now has Phase 3 frontline data emerging from
NCT07211958 (with 7+3) and
NCT06652438 (with HMA + venetoclax). Ziftomenib (
NCT07007312) and bleximenib (
NCT06852222,
NCT07223814) are advancing in parallel.
NPM1-mutated patients — the largest single AML subtype — should ask about menin inhibitor trial eligibility. Separately, the FLT3 inhibitor class is expanding into
FLT3-ITD negative disease with
NCT06578247 (quizartinib + chemo).
Recruiting Trials by Molecular Subtype
NPM1-Mutated / KMT2A-Rearranged — Menin Inhibitors
The most active drug class in AML in 2026. Menin inhibitors disrupt the menin–KMT2A interaction needed for HOX/MEIS1 gene activation in NPM1-mutated and KMT2A-rearranged leukemias. Three agents are in Phase 3 simultaneously in both newly diagnosed and relapsed/refractory settings:
- NCT07211958 - Revumenib + intensive chemo (7+3) in newly diagnosed NPM1-mutated AML (Phase 3)
- NCT06652438 - Revumenib + Azacitidine + Venetoclax in NPM1-mutated or KMT2A-rearranged AML (Phase 3)
- NCT07007312 - Ziftomenib + Venetoclax/Azacitidine or 7+3 in untreated NPM1-m or KMT2A-r AML (Phase 3)
- NCT06852222 - Bleximenib + Venetoclax + Azacitidine in newly diagnosed AML (Phase 3)
- NCT07223814 - Bleximenib + standard induction and consolidation followed by maintenance in newly diagnosed AML (Phase 3)
FLT3-Mutated and FLT3-ITD Negative
FLT3-ITD and FLT3-TKD mutations occur in ~30% of AML. Trials combine FLT3 inhibitors with venetoclax, optimize post-transplant maintenance, and (new in 2026) extend the class into FLT3-ITD negative AML:
- NCT04293562 - CPX-351 and/or Gilteritinib vs standard chemo in newly diagnosed AML ± FLT3 mutations (Phase 3)
- NCT05586074 - HEC73543 vs salvage chemo in relapsed/refractory FLT3-ITD AML (Phase 3)
- NCT07463651 - MRD-guided maintenance post-transplant: Gilteritinib vs Sorafenib (Phase 3)
- NCT06578247 - Quizartinib or placebo + chemotherapy in newly diagnosed FLT3-ITD negative AML (Phase 3) — first Phase 3 extending a FLT3 inhibitor into FLT3 wild-type disease
IDH1/IDH2-Mutated
- NCT07075016 - Ivosidenib + Azacitidine ± Venetoclax in newly diagnosed IDH1-mutated AML ineligible for intensive chemo (Phase 3)
- NCT06387069 - HMPL-306 (dual IDH1/2 inhibitor) in IDH1 or IDH2-mutated AML (Phase 3)
- NCT05907057 - Ivosidenib + Azacitidine in newly diagnosed IDH1m AML (Phase 3b)
TP53-Mutated
The highest unmet need in AML — TP53-mutated disease has extremely poor prognosis with current therapies. Multiple novel agents are in development including combinations with HMA + venetoclax backbones. Search ClinTrialFinder with your TP53 status to surface eligible trials in this rapidly changing space.
Trials by Treatment Setting
Newly Diagnosed — Intensive (Fit Patients)
- NCT04628026 - Induction and consolidation chemo with Venetoclax in newly diagnosed AML/MDS-EB-2 (Phase 3)
- NCT05805098 - Venetoclax + Homoharringtonine + Cytarabine induction (Phase 3)
- NCT06810791 - HVA vs IA/DA or VA in high-risk AML (Phase 3)
- NCT05939180 - VA vs DA for newly diagnosed high-risk AML (Phase 3)
- NCT02416388 - Daunorubicin vs high-dose Idarubicin, intermediate vs high-dose cytarabine (Phase 3)
- NCT04168502 - Gemtuzumab ozogamicin MRD-guided in favorable/intermediate risk AML (Phase 3)
Newly Diagnosed — Non-Intensive (Unfit/Elderly)
- NCT06389292 - Lisaftoclax (APG-2575, next-gen BCL-2) + Azacitidine in AML (Phase 3)
- NCT04256317 - AZTOUND: ASTX030 (oral azacitidine) ± Venetoclax (Phase 3)
- NCT07132684 - VA vs D/IA induction in elderly fit AML (Phase 3)
- NCT06345365 - MA + AZA regimen for newly diagnosed AML (Phase 3)
Relapsed / Refractory
- NCT06713837 - IMPACT-AML: Pragmatic clinical trial for R/R AML (Phase 3)
- NCT06418776 - IMPACT-AML: Randomized pragmatic trial for R/R AML (Phase 3)
- NCT06788756 - L-Annamycin + Cytarabine second-line remission induction (Phase 3)
- NCT05726110 - Selinexor + HAD or CAG in R/R AML (Phase 3)
Maintenance / Post-Remission
- NCT05404906 - Azacitidine + Venetoclax maintenance in younger adults with AML in first remission (Phase 3)
- NCT06972641 - Molecular genetics-guided maintenance after allo-HSCT (Phase 3)
- NCT06802718 - Interferon-alpha maintenance for favorable-risk AML (Phase 3)
- NCT06990321 - Medium-dose cytarabine + Venetoclax consolidation in elderly intermediate/high-risk AML (Phase 3)
Transplant Optimization
- NCT04314219 - Post-transplant cyclophosphamide vs SOC GVHD prophylaxis (Phase 3)
- NCT05429632 - Mocravimod adjunctive and maintenance in AML patients undergoing allo-HCT (Phase 3)
- NCT04708054 - Venetoclax to improve outcomes of busulfan conditioning in high-risk AML/MDS (Phase 3)
- NCT07396480 - Fludarabine + Melphalan ± Venetoclax conditioning for allo-HCT in AML/MDS patients >50 years (Phase 3)
- NCT05991908 - Fludarabine + single vs dual alkylating agent conditioning in myeloid malignancies (Phase 3)
- NCT05477589 - SCRIPT-AML: Pediatric AML conditioning regimen study (Phase 3)
- NCT03793517 - Decitabine + mBU/CY for high-risk acute leukemia with MRD pre-HSCT (Phase 3)
Novel Approaches
- Menin inhibitors: Revumenib, ziftomenib, bleximenib — first targeted therapy for NPM1-mutated AML (30% of AML), all reaching Phase 3 in 2026
- Next-gen BCL-2 inhibitors: Lisaftoclax (APG-2575), sonrotoclax — designed to improve on venetoclax
- Dual IDH inhibitors: HMPL-306 targeting both IDH1 and IDH2 mutations with a single agent
- MRD-guided therapy: Multiple trials using measurable residual disease to guide maintenance and transplant decisions
- Oral azacitidine combinations: ASTX030 (cedazuridine + azacitidine) enabling fully oral regimens
- Pediatric AML: NCT05183035 - Venetoclax in children with R/R AML; NCT05994690 - CHIP-AML22 master protocol
Frequently Asked Questions
How do I find AML clinical trials for my mutation?
Paste your medical summary into ClinTrialFinder to get AI-matched AML trials in minutes. The tool considers your NPM1 status, FLT3-ITD/TKD mutations, IDH1/IDH2 mutations, KMT2A rearrangements, TP53 mutations, CBF translocations, cytogenetic risk group, and prior treatments including transplant history.
What AML trials are currently recruiting?
There are 496 recruiting interventional trials for AML in July 2026, of which 47 are Phase 3 (or Phase 2/3). They include menin inhibitors for NPM1-mutated and KMT2A-rearranged disease (revumenib, ziftomenib, bleximenib), venetoclax-based combinations, FLT3 inhibitors (gilteritinib, quizartinib — now expanding into FLT3-ITD negative AML), IDH1/2 inhibitors, TP53-directed therapies, and transplant / cellular approaches including CAR-T.
Are there menin inhibitor trials open for NPM1-mutated AML?
Yes. NPM1-mutated AML is one of the most active subtypes in 2026. Three menin inhibitors are in Phase 3 for NPM1-mutated and/or KMT2A-rearranged AML: revumenib (NCT07211958 with intensive chemo in newly diagnosed; NCT06652438 with azacitidine + venetoclax), ziftomenib (NCT07007312 with venetoclax/azacitidine or 7+3 in untreated), and bleximenib (NCT06852222 with venetoclax + azacitidine; NCT07223814 with standard induction/consolidation + maintenance). NPM1 mutations occur in roughly 30% of adult AML.
Find AML Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific mutations, risk group, and treatment history.
Find Matching Trials
